DRUG · Mapped RxNorm record
Zidovudine
Normalized identity: zidovudine View linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
A Randomized, Double Blind, Comparative Study of Dideoxycytidine (ddC) Alone or ddC/AZT Combination Versus Zidovudine (ZDV) Alone in Patients With HIV Infection Who Have Received Prior ZDV Therapy
NCT00000651
Study summary
ClinicalTrials.govA Randomized, Double Blind, Comparative Study of Dideoxycytidine (ddC) Alone or ddC/AZT Combination Versus Zidovudine (ZDV) Alone in Patients With HIV Infection Who Have Received Prior ZDV Therapy
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3
Loading study purpose, treatment groups and outcomes…
View the complete registry record, eligibility and contacts at ClinicalTrials.gov
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
Zalcitabine
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Advertisement
Conditions
HIV Infectionsunresolved
Interventions
ZidovudineDRUG · verified · RxNorm: zidovudine
ZalcitabineDRUG
Sponsors & collaborators
Hoffmann-La Rochecollaborator
Glaxo Wellcomecollaborator
Mapped research locations
BostonMassachusetts, United States6New YorkNew York, United States5ChicagoIllinois, United States2Los AngelesCalifornia, United States2St LouisMissouri, United States2San DiegoCalifornia, United States2New OrleansLouisiana, United States2BaltimoreMaryland, United States1MiamiFlorida, United States1San FranciscoCalifornia, United States1SeattleWashington, United States1ClevelandOhio, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00000651 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.